# OP \$65.00 87443234

# TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 ETAS ID: TM436827

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL

### **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
IMPRIMIS PHARMACEUTICALS, INC.		07/24/2017	Corporation:

## **RECEIVING PARTY DATA**

Name:	ETON PHARMACEUTICALS, INC.
Street Address:	21925 Field Parkway, Suite 235
City:	Deer Park
State/Country:	ILLINOIS
Postal Code:	60010
Entity Type:	Corporation: DELAWARE

## **PROPERTY NUMBERS Total: 2**

Property Type	Number	Word Mark
Serial Number:	87443234	ETON PHARMACEUTICALS
Serial Number:	87443236	ETON

## **CORRESPONDENCE DATA**

**Fax Number:** 6193742089

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 8585924141

**Email:** office@wageniplaw.com, aj@wageniplaw.com

Correspondent Name: Wagenknecht IP LAW Group pc
Address Line 1: 12396 World trade drive, suite 312
Address Line 4: San Diego, CALIFORNIA 92128

NAME OF SUBMITTER:	Allen Isabelo
SIGNATURE:	/Allen Isabelo/
DATE SIGNED:	07/27/2017

## **Total Attachments: 3**

source=20243-301517 Assignment#page1.tif source=20243-301517 Assignment#page2.tif source=20243-301517 Assignment#page3.tif

> TRADEMARK REEL: 006115 FRAME: 0771

900415022

# ASSIGNMENT OF TRADEMARKS

The undersigned (hereinafter collectively referred to as the Assignor), in consideration of the sum of one US dollar (\$ 1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, hereby sell, assign, and transfer to:

## **Eton Pharmaceuticals**

(hereinafter referred to as the Assignee), of

# 21925 Field Parkway, Suite 235 Deer Park, IL 60010 USA

my entire right, title and interest for the United States of America, including its territories and possessions, and throughout the world, to the following trademarks, together with all associated goodwill, whether registered or unregistered, whether in word form, design form, or a combination thereof, and for which US trademark applications were filed:

Mark	US Application No.	Filing Date
ETON	87/443,236	May 9, 2017
ETON PHARMACEUTICALS	87/443,234	May 9, 2017

the Assignee being a successor to the portion of the Assignor's ongoing existing business to which the trademark pertains.

Assignment US Serial No. 87/443,234 US Serial No. 87/443,236

The Assignor hereby represents to have full right to convey the interest herein assigned, and has not executed, and will not execute, any agreement in conflict therewith.

Mark L. Baum, Chief Executive Officer
Imprimis Pharmaceuticals, Inc.

7-24-2017

Date

This Assignment is accepted by ETON PHARMACEUTICALS

Signature:		
Name:	Sean Brynjelsen	
Γitle:	Chief Executive Officer	

Assignment US Serial No. 87/443,234 US Serial No. 87/443,236

The Assignor hereby represents to have full right to convey the interest herein assigned, and has not executed, and will not execute, any agreement in conflict therewith.

Mark L. Baum, Chief Executive Officer
Imprimis Pharmaceuticals, Inc.

This Assignment is accepted by ETON PHARMACEUTICALS

Signature:

Sean Brynjelsen

Title:

Chief Executive Officer

**RECORDED: 07/27/2017** 

TRADEMARK REEL: 006115 FRAME: 0774